Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme.
Heidenreich A, Scholz HJ, Rogenhofer S, Arsov C, Retz M, Müller SC, Albers P, Gschwend J, Wirth M, Steiner U, Miller K, Heinrich E, Trojan L, Volkmer B, Honecker F, Bokemeyer C, Keck B, Otremba B, Ecstein-Fraisse E, Pfister D.
Heidenreich A, et al. Among authors: heinrich e.
Eur Urol. 2013 Jun;63(6):977-82. doi: 10.1016/j.eururo.2012.08.058. Epub 2012 Sep 3.
Eur Urol. 2013.
PMID: 23116658